![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults
With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I)
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 san Francisco, CA
Tarik Asselah1, Tarek I Hassanein2, Roula B Qaqish3, Jordan J Feld4, Christophe Hezode5, Stefan Zeuzem6, Peter Ferenci7, Tami Pilot-Mati as3, Yao Yu3, Rebecca Redman3, Niloufar Mobashery3
1Centre de Recherche sur l'Infl ammati on, Inserm UMR 1149, Universite Paris Diderot, AP-HP Hopital Beaujon, Clichy, France; 2Southern California Liver Centers and Southern California Research Center, Coronado, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States;
4Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 5Henri Mondor University Hospital, AP-HP, Universite Paris-Est, Creteil, France; 6JW Goethe University, Frankfurt, Germany; 7Medical University Vienna, Vienna, Austria
![AASLD1.gif](../images/111815/111815-1/AASLD1.gif)
![AASLD2.gif](../images/111815/111815-1/AASLD2.gif)
![AASLD3.gif](../images/111815/111815-1/AASLD3.gif)
![AASLD4.gif](../images/111815/111815-1/AASLD4.gif)
![AASLD5.gif](../images/111815/111815-1/AASLD5.gif)
![AASLD6.gif](../images/111815/111815-1/AASLD6.gif)
![AASLD7.gif](../images/111815/111815-1/AASLD7.gif)
![AASLD8.gif](../images/111815/111815-1/AASLD8.gif)
![AASLD9.gif](../images/111815/111815-1/AASLD9.gif)
![AASLD10.gif](../images/111815/111815-1/AASLD10.gif)
![AASLD11.gif](../images/111815/111815-1/AASLD11.gif)
![AASLD12.gif](../images/111815/111815-1/AASLD12.gif)
![AASLD13.gif](../images/111815/111815-1/AASLD13.gif)
![AASLD14.gif](../images/111815/111815-1/AASLD14.gif)
![AASLD15.gif](../images/111815/111815-1/AASLD15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|